Moreover, our investigation of paired primary tumors and LN metastatic tumors revealed that 63.8% of TNBC patients exhibited higher expression of MAP7D3, which was in line with our cell-based experiments (Fig. 1G J). The gene discussed is MAP7D3; the disease is metastatic neoplasm.